PF-299804 (dacomitinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PF-299804 (dacomitinib), covering 2021-07-06 to 2021-07-06. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. [Phase 2]